- 17 Jan 2019
PledPharma will present its “first in class” drug candidate PledOx phase III program at the Gastrointestinal (GI) Cancers Symposium, taking place in San Francisco today and tomorrow.
- 17 Jan 2019
Actelion Pharmaceuticals will need to provide more data to evaluate the use of Opsumit in the treatment of adults with inoperable chronic thromboembolic pulmonary hypertension.
- 17 Jan 2019
Roche will wait until September 2019 for the FDA’s decision, before it can combine Tecentriq with Abraxane and carboplatin for the first-line treatment of lung cancer patients, who don’t have EGFR or ALK genomic tumour aberrations.
- 17 Jan 2019
Innovent Biologics has started testing on patients its Tyvyt, fully human anti-PD-1 therapeutic monoclonal antibody, with generic name sintilimab injection, in combination with capecitabine and oxaliplatin, patients with advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (GC or GEJ).
- 17 Jan 2019
- 17 Jan 2019
Geron Corporation has included the first of several key leadership positions in rebuilding its in-house development team to boost a Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes by mid-year 2019.
- 17 Jan 2019
- 16 Jan 2019
ADC Therapeutics, oncology drug specialist started the Phase I clinical testing ADCT-601 on patients with selected solid tumors that are locally advanced or metastatic.
My Pharmaceutical
Consequences of microbead: What makes microbeads problematic
In the world of great discoveries that cure or add a positive element to our everyday existence, the invention of microbeads hasn’t proven to be one of them. Not alone in its quick rise to popularity and slow journey to extinction, the microbead is just one of numerous products rushed to market before its long term effects are uncovered.
